News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abiogen Pharma's New Cell Therapy Starts A Clinical Phase I-II In Peritoneal Carcinosis



10/19/2005 5:13:04 PM

PISA, Italy--(BUSINESS WIRE)--April 18, 2005--Abiogen Pharma today announced the start of a Phase I-II clinical trial in Italy using ABIO 05/01 cells for the treatment of peritoneal carcinosis. The Phase I-II trial on peritoneal cancer patients will be conducted at the Oncology-Haematology Department of the University of Modena. The study will enrol approximately 18 patients with advanced tumors who have not responded to existing therapies. The purpose of the Phase I-II study is to evaluate ABIO 05/01's safety in humans and to establish safe dose ranges for further studies. ABIO 05/01 is a cytotoxic cell line derived from the cells of a child with a rare form of T-cell leukaemia by Daniela Santoli, Ph.D., a professor at The Wistar Institute in Philadelphia. In vitro and in vivo, ABIO 05/01 cells have successfully caused the regression and disappearance of certain tumors without affecting normal tissue or producing side effects.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES